These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 30670411)
41. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866 [TBL] [Abstract][Full Text] [Related]
42. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model. Gill CM; Abdelraouf K; Nicolau DP J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033 [TBL] [Abstract][Full Text] [Related]
44. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512 [TBL] [Abstract][Full Text] [Related]
45. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Castanheira M; Huband MD; Mendes RE; Flamm RK Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234 [TBL] [Abstract][Full Text] [Related]
46. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205 [TBL] [Abstract][Full Text] [Related]
47. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center. Kulengowski B; Burgess DS Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075 [TBL] [Abstract][Full Text] [Related]
48. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044 [TBL] [Abstract][Full Text] [Related]
49. Emergence of extended-spectrum β-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae (CPE) and their antimicrobial resistance. Koren J; Hubenakova Z; Drahovska H; Ozaee E; Markuskova B; Lichvarikova A Bratisl Lek Listy; 2019; 120(12):935-940. PubMed ID: 31855054 [TBL] [Abstract][Full Text] [Related]
50. 1,4,7-Triazacyclononane Restores the Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Somboro AM; Amoako DG; Osei Sekyere J; Kumalo HM; Khan R; Bester LA; Essack SY Appl Environ Microbiol; 2019 Feb; 85(3):. PubMed ID: 30478231 [TBL] [Abstract][Full Text] [Related]
51. SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model. Leiris S; Coelho A; Castandet J; Bayet M; Lozano C; Bougnon J; Bousquet J; Everett M; Lemonnier M; Sprynski N; Zalacain M; Pallin TD; Cramp MC; Jennings N; Raphy G; Jones MW; Pattipati R; Shankar B; Sivasubrahmanyam R; Soodhagani AK; Juventhala RR; Pottabathini N; Pothukanuri S; Benvenuti M; Pozzi C; Mangani S; De Luca F; Cerboni G; Docquier JD; Davies DT ACS Infect Dis; 2019 Jan; 5(1):131-140. PubMed ID: 30427656 [TBL] [Abstract][Full Text] [Related]
52. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Lee YR; Baker NT Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787 [TBL] [Abstract][Full Text] [Related]
54. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. Novelli A; Del Giacomo P; Rossolini GM; Tumbarello M Expert Rev Anti Infect Ther; 2020 Jul; 18(7):643-655. PubMed ID: 32297801 [TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model. VanScoy BD; Trang M; McCauley J; Conde H; Bhavnani SM; Friedrich LV; Alexander DC; Ambrose PG Antimicrob Agents Chemother; 2016 Jul; 60(7):3891-6. PubMed ID: 27001820 [TBL] [Abstract][Full Text] [Related]
56. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2015 May; 59(5):2688-94. PubMed ID: 25712356 [TBL] [Abstract][Full Text] [Related]
57. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267 [TBL] [Abstract][Full Text] [Related]
59. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. DeRyke CA; Banevicius MA; Fan HW; Nicolau DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197 [TBL] [Abstract][Full Text] [Related]
60. High prevalence of fecal carriage of Extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae among food handlers at the University of Gondar, Northwest Ethiopia. Amare A; Eshetie S; Kasew D; Moges F PLoS One; 2022; 17(3):e0264818. PubMed ID: 35298493 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]